Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, June 13th. The shares were sold at an average price of $217.71, for a total transaction of $10,885,500.00. Following the sale, the chief executive officer now owns 272,122 shares of the company’s stock, valued at $59,243,680.62. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Thermo Fisher Scientific stock opened at $215.80 on Monday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 0.95. Thermo Fisher Scientific Inc. has a 1 year low of $170.07 and a 1 year high of $226.44. The company has a market cap of $86.82 billion, a P/E ratio of 22.74, a P/E/G ratio of 1.58 and a beta of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 25th. The medical research company reported $2.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.08. Thermo Fisher Scientific had a return on equity of 16.09% and a net margin of 10.24%. The firm had revenue of $5.85 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same period in the previous year, the firm posted $2.08 EPS. The company’s quarterly revenue was up 22.8% compared to the same quarter last year. analysts forecast that Thermo Fisher Scientific Inc. will post 10.9 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 16th. Investors of record on Friday, June 15th will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio is currently 7.17%.

A number of research firms have recently issued reports on TMO. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $216.00 to $230.00 and gave the company an “overweight” rating in a research report on Thursday, April 26th. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, May 16th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average target price of $224.38.

Several institutional investors have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $1,507,000. Private Vista LLC acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $288,000. Dundas Partners LLP acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $7,100,000. Nicola Wealth Management LTD. acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $5,104,000. Finally, Chesapeake Wealth Management acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $856,000. Hedge funds and other institutional investors own 85.85% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.